Mobocertinib succinate

Mobocertinib succinate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research.

• Verwenden

  Mobocertinib is an oral targeted therapy drug^[1].Mobocertinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has spread to other parts of the body either during or after treatment with platinum chemotherapy medications.
  

• Mechanism of action

  Mobocertinib acts to inhibit EGFR exon 20 insertion mutations at a lower concentration than it does on wild-type proteins.

• Nebenwirkungen

  Diarrhoea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin,musculoskeletal pain, increased amylase/lipase/creatinine, and decreased potassium/hemoglobin/magnesium/lymphocytes.
  

• Synthese

  Mobocertinib succinate is prepared by the reaction of Isopropyl 2-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate in the presence of an inert atmosphere.
  

• Einzelnachweise

  [1] IMRANMOHD. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.[J]. Biomedicines, 2021. DOI:10.3390/biomedicines9121938.

Mobocertinib succinate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(67)Suppliers